CML

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg

Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

Study of Olverembatinib (HQP1351) in Patients With CP-CML

Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction

Study of Treatment Free Remission in Patients With Chronic Myeloid Leukemia in Chronic Phase

Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium

FLOR3 Gene Polymorphism in Predicting Outcomes of Tyrosine Kinase Inhibitor（TKI）Stopping in Chronic Myeloid Leukemia

Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations

An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints

Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy

Palatability (Taste) of Oral Formulations of Bosutinib

A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation

Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies

Sirolimus in Combination With MEC in High Risk Myeloid Leukemias

Tasigna in Glivec-resistant or Intolerant Patients in CML